Charles E Leonard

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4833966/publications.pdf

Version: 2024-02-01

361388 414395 1,212 80 20 32 citations h-index g-index papers 83 83 83 1594 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Validation of diagnostic codes for outpatientâ€originating sudden cardiac death and ventricular arrhythmia in Medicaid and Medicare claims data. Pharmacoepidemiology and Drug Safety, 2010, 19, 555-562.	1.9	109
2	Antidepressants and the risk of sudden cardiac death and ventricular arrhythmia. Pharmacoepidemiology and Drug Safety, 2011, 20, 903-913.	1.9	91
3	Proton pump inhibitors and traditional nonsteroidal antiâ€inflammatory drugs and the risk of acute interstitial nephritis and acute kidney injury. Pharmacoepidemiology and Drug Safety, 2012, 21, 1155-1172.	1.9	74
4	Quality of Medicaid and Medicare Data Obtained Through Centers for Medicare and Medicaid Services (CMS). Medical Care, 2007, 45, 1216-1220.	2.4	63
5	Comparative risk of serious hypoglycemia with oral antidiabetic monotherapy: A retrospective cohort study. Pharmacoepidemiology and Drug Safety, 2018, 27, 9-18.	1.9	50
6	Cisapride and ventricular arrhythmia. British Journal of Clinical Pharmacology, 2008, 66, 375-385.	2.4	47
7	Patient Reported Receipt of Medication Instructions for Warfarin is Associated with Reduced Risk of Serious Bleeding Events. Journal of General Internal Medicine, 2008, 23, 1589-1594.	2.6	33
8	Antipsychotics and the Risks of Sudden Cardiac Death and All-Cause Death: Cohort Studies in Medicaid and Dually Eligible Medicaid-Medicare Beneficiaries of Five States. Journal of Clinical & Experimental Cardiology, 2012, 01, 1-9.	0.0	33
9	Sentinel Modular Program for Propensity Score–Matched Cohort Analyses. Epidemiology, 2017, 28, 838-846.	2.7	32
10	Pro- and Antiarrhythmic Actions of Sulfonylureas: Mechanistic and Clinical Evidence. Trends in Endocrinology and Metabolism, 2017, 28, 561-586.	7.1	31
11	Risk of Nonunion with Nonselective NSAIDs, COX-2 Inhibitors, and Opioids. Journal of Bone and Joint Surgery - Series A, 2020, 102, 1230-1238.	3.0	31
12	Risk for Recurrent Venous Thromboembolism and Bleeding With Apixaban Compared With Rivaroxaban: An Analysis of Real-World Data. Annals of Internal Medicine, 2022, 175, 20-28.	3.9	31
13	Diagnostic E-codes for commonly used, narrow therapeutic index medications poorly predict adverse drug events. Journal of Clinical Epidemiology, 2008, 61, 561-571.	5.0	29
14	Assessment of Physician Prescribing of Muscle Relaxants in the United States, 2005-2016. JAMA Network Open, 2020, 3, e207664.	5.9	28
15	The quality of Medicaid and Medicare data obtained from CMS and its contractors: implications for pharmacoepidemiology. BMC Health Services Research, 2017, 17, 304.	2.2	27
16	Comparative Safety of Sulfonylureas and the Risk of Sudden Cardiac Arrest and Ventricular Arrhythmia. Diabetes Care, 2018, 41, 713-722.	8.6	26
17	Comparative Risk of Ischemic Stroke Among Users of Clopidogrel Together With Individual Proton Pump Inhibitors. Stroke, 2015, 46, 722-731.	2.0	25
18	Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Valvular Atrial Fibrillation. Annals of Internal Medicine, 2021, 174, 910-919.	3.9	25

#	Article	IF	CITATIONS
19	Diagnostic codes for sudden cardiac death and ventricular arrhythmia functioned poorly to identify outpatient events in EPIC's General Practice Research Database. Pharmacoepidemiology and Drug Safety, 2008, 17, 1131-1136.	1.9	23
20	Instantaneous preference was a stronger instrumental variable than 3- and 6-month prescribing preference for NSAIDs. Journal of Clinical Epidemiology, 2008, 61, 1285-1288.	5.0	22
21	Biomedical Informatics Approaches to Identifying Drug–Drug Interactions. Epidemiology, 2017, 28, 459-468.	2.7	22
22	Gastrointestinal bleeding and intracranial hemorrhage in concomitant users of warfarin and antihyperlipidemics. International Journal of Cardiology, 2017, 228, 761-770.	1.7	21
23	CYP2C9, CYP2C19, and ABCB1 Genotype and Hospitalization for Phenytoin Toxicity. Journal of Clinical Pharmacology, 2009, 49, 1483-1487.	2.0	20
24	Chart validation of inpatient <scp>ICDâ€9 M</scp> administrative diagnosis codes for acute myocardial infarction (<scp>AMI</scp>) among intravenous immune globulin (<scp>IGIV</scp>) users in the <scp>S</scp> entinel <scp>D</scp> istributed <scp>D</scp> atabase. Pharmacoepidemiology and Drug Safety, 2018, 27, 398-404.	1.9	18
25	Serious Hypoglycemia and Use of Warfarin in Combination With Sulfonylureas or Metformin. Clinical Pharmacology and Therapeutics, 2019, 105, 210-218.	4.7	17
26	Screening to identify signals of opioid drug interactions leading to unintentional traumatic injury. Biomedicine and Pharmacotherapy, 2020, 130, 110531.	5 . 6	17
27	The Trend-in-trend Research Design for Causal Inference. Epidemiology, 2017, 28, 529-536.	2.7	16
28	The risk of sudden cardiac arrest and ventricular arrhythmia with rosiglitazone versus pioglitazone: real-world evidence on thiazolidinedione safety. Cardiovascular Diabetology, 2020, 19, 25.	6.8	16
29	Researchers and HIPAA. Epidemiology, 2007, 18, 518.	2.7	13
30	Biosimilar Uptake in Academic and Veterans Health Administration Settings: Influence of Institutional Incentives. Arthritis and Rheumatology, 2020, 72, 1067-1071.	5 . 6	13
31	Empiric Potassium Supplementation and Increased Survival in Users of Loop Diuretics. PLoS ONE, 2014, 9, e102279.	2.5	13
32	Clopidogrel Drug Interactions and Serious Bleeding: Generating Realâ€World Evidence via Automated High‶hroughput Pharmacoepidemiologic Screening. Clinical Pharmacology and Therapeutics, 2019, 106, 1067-1075.	4.7	12
33	Diagnostic Algorithms for Cardiovascular Death in Administrative Claims Databases: A Systematic Review. Drug Safety, 2019, 42, 515-527.	3.2	12
34	Preoperative Sedative-hypnotic Medication Use and Adverse Postoperative Outcomes. Annals of Surgery, 2021, 274, e108-e114.	4.2	11
35	Validity of <scp>ICDâ€10â€CM</scp> diagnoses to identify hospitalizations for serious infections among patients treated with biologic therapies. Pharmacoepidemiology and Drug Safety, 2021, 30, 899-909.	1.9	11
36	Comparative Safety of Sodium–Glucose Cotransporter 2 Inhibitors Versus Dipeptidyl Peptidase 4 Inhibitors and Sulfonylureas on the Risk of Diabetic Ketoacidosis. Diabetes Care, 2022, 45, 919-927.	8.6	11

#	Article	IF	CITATIONS
37	Pharmacoepidemiologic Screening of Potential Oral Anticoagulant Drug Interactions Leading to Thromboembolic Events. Clinical Pharmacology and Therapeutics, 2020, 108, 377-386.	4.7	8
38	Effect of statins on the association between high temperature and all-cause mortality in a socioeconomically disadvantaged population: a cohort study. Scientific Reports, 2019, 9, 4685.	3. 3	7
39	Nonsteroidal anti-inflammatory drug choice and adverse outcomes in clopidogrel users: A retrospective cohort study. PLoS ONE, 2018, 13, e0193800.	2.5	7
40	Comparative risk of severe hypoglycemia among concomitant users of thiazolidinedione antidiabetic agents and antihyperlipidemics. Diabetes Research and Clinical Practice, 2016, 115, 60-67.	2.8	6
41	Evaluation of the US Food and Drug Administration sentinel analysis tools in confirming previously observed drugâ€outcome associations: The case of clindamycin and ⟨i⟩Clostridium difficile⟨/i⟩ infection. Pharmacoepidemiology and Drug Safety, 2018, 27, 731-739.	1.9	6
42	Impact of Hospitalization and Medication Switching on Postâ€discharge Adherence to Oral Anticoagulants in Patients With Atrial Fibrillation. Pharmacotherapy, 2020, 40, 1022-1035.	2.6	6
43	Risk of sudden cardiac arrest and ventricular arrhythmia with sulfonylureas: An experience with conceptual replication in two independent populations. Scientific Reports, 2020, 10, 10070.	3.3	6
44	Populationâ€Based Signals of Antidepressant Drug Interactions Associated With Unintentional Traumatic Injury. Clinical Pharmacology and Therapeutics, 2021, 110, 409-423.	4.7	6
45	Angiotensinâ€Converting Enzyme Inhibitors Used Concomitantly with Insulin Secretagogues and the Risk of Serious Hypoglycemia. Clinical Pharmacology and Therapeutics, 2022, 111, 218-226.	4.7	6
46	Comment on: "Desideratum for Evidence-Based Epidemiology― Drug Safety, 2015, 38, 101-103.	3.2	5
47	Pharmacosafety of fluoroquinolone and macrolide antibiotics in the clinical care of patients with myasthenia gravis. Muscle and Nerve, 2021, 64, 156-162.	2.2	5
48	Research and scholarly methods: Propensity scores. JACCP Journal of the American College of Clinical Pharmacy, 2022, 5, 467-475.	1.0	5
49	Additional data on citalopram and the risk of sudden cardiac death and ventricular arrhythmia. Pharmacoepidemiology and Drug Safety, 2012, 21, 331-332.	1.9	4
50	Thromboembolic and neurologic sequelae of discontinuation of an antihyperlipidemic drug during ongoing warfarin therapy. Scientific Reports, 2017, 7, 18037.	3.3	4
51	Evaluation of the US Food and Drug Administration Sentinel Analysis Tools Using a Comparator with a Different Indication: Comparing the Rates of Gastrointestinal Bleeding in Warfarin and Statin Users. Pharmaceutical Medicine, 2019, 33, 29-43.	1.9	4
52	Sulfonylureas and Metformin Were Not Associated With an Increased Rate of Serious Bleeding in Warfarin Users: A Selfâ€Controlled Case Series Study. Clinical Pharmacology and Therapeutics, 2020, 108, 1010-1017.	4.7	4
53	Signals of Muscle Relaxant Drug Interactions Associated with Unintentional Traumatic Injury: A Population-Based Screening Study. CNS Drugs, 2022, 36, 389-400.	5.9	4
54	Opioid Drug-Drug-Drug Interactions and Unintentional Traumatic Injury: Screening to Detect Three-Way Drug Interaction Signals. Frontiers in Pharmacology, 2022, 13, .	3 . 5	4

#	Article	IF	CITATIONS
55	Response to commentary entitled $\hat{a}\in Commentary$ on the validation studies of sudden cardiac death and ventricular arrhythmia by Hennessy <i>et al</i> . and Chung <i>et al</i> . $\hat{a}\in M$. Pharmacoepidemiology and Drug Safety, 2010, 19, 576-576.	1.9	3
56	Twelveâ€year trends in pharmacologic treatment of type 2 diabetes among patients with heart failure in the United States. Diabetes, Obesity and Metabolism, 2020, 22, 705-710.	4.4	3
57	National outpatient medication utilization for opioid and alcohol use disorders from 2014 to 2016. Journal of Substance Abuse Treatment, 2020, 119, 108141.	2.8	3
58	Knowledge of biosimilars and perceptions of the naming conventions for biosimilar products in clinical practice in the United States. Drugs and Therapy Perspectives, 2021, 37, 338-346.	0.6	3
59	Comparative Safety of Dipeptidyl Peptidaseâ€4 Inhibitors and Sudden Cardiac Arrest and Ventricular Arrhythmia: Populationâ€Based Cohort Studies. Clinical Pharmacology and Therapeutics, 2021, , .	4.7	3
60	Skeletal muscle relaxant drug–drug–drug interactions and unintentional traumatic injury: Screening to detect threeâ€way drug interaction signals. British Journal of Clinical Pharmacology, 2022, 88, 4773-4783.	2.4	3
61	A System for De-identifying Medical Message Board Text. , 2010, , .		2
62	The Selfâ€Controlled Case Series Design as a Viable Alternative to Studying Clinically Relevant Drug Interactions. Clinical Pharmacology and Therapeutics, 2020, 107, 321-322.	4.7	2
63	Compared to commercially insured patients, Medicare advantage patients adopt newer diabetes drugs more slowly and adhere to them less. Endocrinology, Diabetes and Metabolism, 2021, 4, e00245.	2.4	2
64	Evaluation of serious bleeding signals during concomitant use of clopidogrel and hypnotic drugs. Biomedicine and Pharmacotherapy, 2021, 139, 111559.	5.6	2
65	Association Between Serious Hypoglycemia and Calcium-Channel Blockers Used Concomitantly With Insulin Secretagogues. JAMA Network Open, 2021, 4, e2124443.	5.9	2
66	Developing a Standardized and Reusable Method to Link Distributed Health Plan Databases to the National Death Index: Methods Development Study Protocol. JMIR Research Protocols, 2020, 9, e21811.	1.0	2
67	Rate of major bleeding with ibrutinib versus bendamustineâ€rituximab in chronic lymphocytic leukemia: A populationâ€based cohort study. American Journal of Hematology, 2022, 97, .	4.1	2
68	Challenges in recruiting subjects to a pilot trial of patient-managed in-hospital insulin. BMC Research Notes, 2015, 8, 523.	1.4	1
69	The Authors Respond. Epidemiology, 2018, 29, e8-e9.	2.7	1
70	Outdoor temperature and survival benefit of empiric potassium in users of furosemide in US Medicaid enrollees: a cohort study. BMJ Open, 2019, 9, e023809.	1.9	1
71	Receipt of Substance Use Counseling Among Ambulatory Patients Prescribed Opioids in the United States. Substance Abuse: Research and Treatment, 2020, 14, 117822181989458.	0.9	1
72	Spotlight commentary: A role for realâ€world evidence to inform the clinical care of patients with diabetes mellitus. British Journal of Clinical Pharmacology, 2021, 87, 4549-4551.	2.4	1

#	Article	IF	CITATIONS
73	Does hospitalization for thromboembolism improve oral anticoagulant adherence in patients with atrial fibrillation?. Journal of the American Pharmacists Association: JAPhA, 2020, 60, 986-992.e2.	1.5	1
74	Knowledge of biosimilars and perceptions of the naming conventions for biosimilar products in clinical practice in the United States. Drugs and Therapy Perspectives, 2021, 37, 338-346.	0.6	1
75	Self-controlled assessment of thromboembolic event (TEE) risk following intravenous immune globulin (IGIV) in the U.S. (2006–2012). Journal of Thrombosis and Thrombolysis, 2021, , 1.	2.1	1
76	Population-based signals of benzodiazepine drug interactions associated with unintentional traumatic injury. Journal of Psychiatric Research, 2022, 151, 299-303.	3.1	1
77	Lost in Translation: No Effect of a Highâ€Profile Publication on the Concomitant Use of Interacting Drugs. Clinical and Translational Science, 2017, 10, 426-430.	3.1	О
78	Cardiovascular and major bleeding outcomes with antiplatelet and direct oral anticoagulants in patients with acute coronary syndrome and atrial fibrillation: A population-based analysis. American Heart Journal, 2021, 242, 71-81.	2.7	0
79	Investigation of Concomitant Use of Alzheimer's Disease Drugs with Sulfonylureas and Serious Hypoglycemia. Epidemiology, 2021, 32, e3-e5.	2.7	0
80	New-onset cancer cases in FDA's Sentinel System: a large distributed system of US electronic healthcare data. Cancer Epidemiology Biomarkers and Prevention, 0, , .	2.5	0